Allianz Asset Management GmbH Sells 5,646 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• Allianz Asset Management GmbH has reduced its holdings in Lantheus Holdings, Inc. by 6.4%, selling 5,646 shares, which brings its total ownership to 82,481 shares valued at approximately $8.05 million.
• In recent transactions, Lantheus insiders, including Director Mary Anne Heino, have sold significant amounts of stock, with Heino selling 26,066 shares for over $2 million, decreasing her ownership by 7.56%.
• Analysts have upgraded Lantheus to a "buy" rating, with a current consensus of "Moderate Buy" and an average price target of $131.20, despite recent earnings results coming in below estimates.

Allianz Asset Management GmbH lowered its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 6.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 82,481 shares of the medical equipment provider's stock after selling 5,646 shares during the period. Allianz Asset Management GmbH owned about 0.12% of Lantheus worth $8,050,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of LNTH. Summit Securities Group LLC bought a new position in shares of Lantheus during the fourth quarter valued at $37,000. Signaturefd LLC raised its stake in shares of Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 116 shares during the last quarter. Hughes Financial Services LLC bought a new position in shares of Lantheus during the first quarter valued at $81,000. UMB Bank n.a. raised its stake in shares of Lantheus by 68.2% during the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after acquiring an additional 381 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Lantheus by 117.7% during the first quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock valued at $114,000 after acquiring an additional 633 shares during the last quarter. Institutional investors own 99.06% of the company's stock.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director directly owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.50% of the company's stock.

Lantheus Trading Up 2.8%

LNTH opened at $72.93 on Friday. Lantheus Holdings, Inc. has a 1-year low of $69.12 and a 1-year high of $118.21. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49. The company has a market cap of $5.05 billion, a P/E ratio of 20.72 and a beta of 0.12. The company has a fifty day moving average price of $78.06 and a two-hundred day moving average price of $88.72.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The company had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. During the same period last year, the firm posted $1.69 earnings per share. The company's revenue for the quarter was up .8% on a year-over-year basis. Analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Truist Financial lowered their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. William Blair reissued a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Finally, B. Riley lowered their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $131.20.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.